Novo Nordisk shares are down another 8 percent after an article from Reuters stating that U.S.-based Hims & Hers Health will begin selling cheaper copies of Novo Nordisk's new Wegovy pill at $49 per month.
In a press release, Novo Nordisk opposed the plans and said the company will "take legal and regulatory action to protect patients, our intellectual property rights and the integrity of the US drug approval framework."
Hims & Hers shares were up 1.1 percent on Wall Street.
